A Randomized Controlled Trial Comparing the Efficacy and Safety of IDegLira Versus Basal-Bolus in Patients With Poorly Controlled Type 2 Diabetes and Very High HbA1c ≥9-15%: DUAL HIGH Trial.
Rodolfo J GalindoBobak MoazzamiMaria F SciosciaCesar ZambranoBonnie S AlburyJarrod SalingPriyathama VellankiFrancisco J PasquelGeorgia M DavisMaya FayfmanLimin PengGuillermo E UmpierrezPublished in: Diabetes care (2023)
In participants with T2D and HbA1c ≥9.0-15.0%, IDegLira resulted in similar HbA1c reduction, less hypoglycemia, and less weight gain compared with the basal-bolus regimen.